Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T2-weighted and diffusion-weighted MRI

NMR in Biomedicine

Volumn 21, Issue 10, 2008, Pages 1021-1029

  Huang, Ming Q ^a   Pickup, Stephen ^a   Nelson, David S ^a   Qiao, Hui ^a   Xu, He N ^a   Li, Lin Z ^a   Zhou, Rong ^a   James Delikatny, E ^a   Poptani, Harish ^a   Glickson, Jerry D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apparent diffusion coefficient; Chemotherapy; MRI; Non Hodgkin's lymphoma; Response; T2

Indexed keywords

APPARENT DIFFUSION COEFFICIENT; COMBINATION CHEMOTHERAPY; DIFFUSE LARGE B-CELL LYMPHOMA; DIFFUSION-WEIGHTED MRI; NON-HODGKIN'S LYMPHOMA; PROLIFERATION AND APOPTOSIS; RESPONSE; T2;

BIOLOGICAL MATERIALS; CELL DEATH; CHEMOTHERAPY; MAGNETIC RESONANCE IMAGING; MAMMALS; ONCOLOGY; PATIENT TREATMENT; SURFACE DIFFUSION;

TUMORS;

ANTINEOPLASTIC AGENT;

ANIMAL; ARTICLE; COMPUTER ASSISTED DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; EVALUATION; FEASIBILITY STUDY; HUMAN; METHODOLOGY; MOUSE; NONHODGKIN LYMPHOMA; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDIES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOMA, NON-HODGKIN; MICE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 59849091285     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1261     Document Type: Article

References (54)

1. Rogers BB. Overview of non-Hodgkin's lymphoma. Semin Oncol Nurs. 2006; 22: 67-72.
2. American Cancer Society. Cancer Facts & Figures 2006. Atlanta, American Cancer Society: 2006.
3. Fisher R. Cyclophosphamide, doxorubicin, vincristine, and pre-dnisone versus intensive chemotherapy in non-Hodgkin's lym-phoma. Cancer Chemother Pharmacol. 1997; 40: S42-S46.
4. 18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2006; 6: 306-313.
5. 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J. Clin Oncol 2005; 23: 4643-1651.
6. Glickson JD. Clinical NMR-spectroscopy of tumors: current status and future-directions. Invest Radiol 1989; 24: 1011-1016.
7. Ng TC, Evanochko WT, Hiramoto RN, Ghanta VK, Lilly MB, Lawson AJ, Corbett TH, Durant JR, Glickson JD. P-31 NMR-spectroscopy of in vivo tumors. J. Magn Reson. 1982; 49: 271-286.
8. Li SJ, Wehrle JP, Rajan SS, Steen RG, Glickson JD, Hilton J. Response of radiation-induced fibrosarcoma-1 in mice to cyclo-phosphamide monitored by in vivo P-31 nuclear magnetic-resonance spectroscopy. Cancer Res 1988; 48: 4736-4742.
9. Wehrle JP, Li SJ, Rajan SS, Steen RG, Glickson JD. P-31 and H-1-NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy. Ann N Y Acad Sci 1987; 508: 200-215.
10. Braunschweiger PG, Kumar N, Constantinidis I, Wehrle JP, Glick-son JD, Johnson CS, Furmanski P. Potentiation of interleukin 1-Alpha mediated antitumor effects by ketoconazole. Cancer Res 1990; 50: 4709-4717.
11. Shungu DC, Bhujwalla ZM, Wehrle JP, Glickson JD. H-1-NMR spectroscopy of subcutaneous tumors in mice: preliminary studies of effects of growth, chemotherapy and blood-flow reduction. NMR Biomed 1992; 5: 296-302.
12. Bhujwalla ZM, Glickson JD. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int J Radiat Oncol Biol Phys 1996; 36: 635-639.
13. Griffiths JR, Tate AR, Howe FA. Stubbs M as part of The Multi-Institutional Group on MRS Application to Cancer. Magnetic resonance spectroscopy of cancer: practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur J Cancer 2002; 38: 2085-2093.
14. Zakian KL, Koutcher JA. Magnetic resonance spectroscopy and clinical cancer prognosis. Acad Radiol 2004; 11: 365-367.
15. Sibtaina NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 2007; 62: 109-119.
16. He Q, Shungu DC, van Zijl PC, Bhujwalla ZM, Glickson JD. Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC) with application to tumors. J. Magn Reson B. 1995; 106: 203-211.
17. Evanochko WT, Sakai TT, Ng TC, Krishna NR, Kim HD, Zeidler RB, Ghanta VK, Brockman RW, Schiffer LM, Braunschweiger PG, Glickson JD. NMR-study of in vivo Rif-1 tumors: analysis of perchloric-acid extracts and identification of H-1-resonances, P-31-resonances and C-13-resonances. Biochim Biophys Acta 1984; 805: 104-116.
18. Evelhoch JL, Sapareto SA, Nussbaum GH, Ackerman JJH. Correlations between P-31 NMR-spectroscopy and O-15 perfusion measurements in the Rif-1 murine tumor in vivo. Radiat Res 1986; 106: 122-131.
19. Negendank WG, Padavicshaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, Brown TR. Metabolic characterization of human non-Hodgkins-lymphomas in-vivo with the use of proton-decoupled phosphorus magnetic-resonance spectroscopy. Cancer Res 1995; 55: 3286-3294.
20. McPhail LD, Chung Y-L, Madhu B, Clark S, Griffiths JR, Kelland LR, Robinson SP. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res. 2005; 11: 3705-3713.
21. Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor contentofphosphoethanolamine plus phosphocholine. Acad Radiol 2004; 11: 368-376.
22. Bourne RM, Stanwell P, Stretch JR, Scolyer RA, Thompson JF, Mountford CE, Lean CL. In vivo and ex vivo proton MR spec-troscopy of primary and secondary melanoma. Eur J Radiol 2005; 53: 506-513.
23. Le Bihan D. Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed. 1995; 8: 375-386.
24. Barboriak DP. Imaging of brain tumors with diffusion-weighted and diffusion tensor MR imaging. Magn Reson Imaging Clin North America. 2003; 11: 379-401.
25. Chenevert TLMP, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic reson-ance imaging. Clin Cancer Res. 1997; 3: 1457-1466.
26. Poptani H, Puumalainen A, Grohn O, Loimas S, Kainulainen R, Yla-Herttuala S, Kauppinen R. Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Therapy. 1998; 5: 101-119.
27. Naganawa S, Sato C, Nakamura T, Kumada H, Ishigaki T, Miura S, Maruyama K, Takizawa O. Diffusion-weighted images of the liver: comparison of tumor detection before and after contrast enhancement with superparamagnetic iron oxide. J. Magn Reson Imaging. 2005; 21: 836-840.
28. Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, Kuranami M, Watanabe M, Hayakawa K. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci. 2005; 4: 35-42.
29. Kuroki Y, Nasu K, Kuroki S, Murakami K, Hayashi T, Sekiguchi R, Nawano S. Diffusion-weighted imaging of breast cancer with the sensitivity encoding technique: analysis of the apparent diffusion coefficient value. Magn Reson Med Sci. 2004; 3: 79-85.
30. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J. Magn Reson Imaging. 2006; 23: 130-134.
31. Minematsu K, Li L, Fisher M, Sotak CH, Davis MA, Fiandaca MS. Diffusion-weighted magnetic resonance imaging: rapid and quantitative detection of focal brain ischemia. Neurology. 1992; 42: 235-240.
32. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging. 2006; 6: 135-143.
33. Stanisz GJ, Odrobina EE, Pun J, Escaravage M, Graham SJ, Bronskill MJ, Henkelman RM. T1, T2 relaxation and magnetization transfer in tissue at 3T. Magn Reson Med. 2005; 54: 507-512.
34. Gambarota G, Veltien A, van Laarhoven H, Philippens M, Jonker A, Mook OR, Frederiks WM, Heerschap A. Measurements of T1 and T2 relaxation times of colon cancer metastases in rat liver at 7T. MAGMA 2004; 17: 281-287.
35. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of Bryostatin 1 to cyclophosphamide, doxorubicin, vin-cristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant Human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950-4956.
36. Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res. 1998; 4: 1305-1314.
37. Mohammad RM, Mohamed AN, KuKuruga M, Smith MR, Al-Katib A. A human B-cell lymphoma line with a de novo multidrug resistance phenotype. Cancer. 1992; 69: 1468-1474.
38. Huang MQ, Nelson DS, Pickup S, Qiao H, Delikatny EJ, Poptani H, Glickson JD. In vivo monitoring response to chemotherapy of human diffuse large B-Cell lymphoma xenografts in SCID mice by H-1 and P-31 MRS. Academic Radiology. Dec 2007; 14(12): 1531-1539.
39. Lee SC, Huang MQ, Nelson DS, Pickup S, Wehrli S, Adegbola O, Poptani H, Delikatny EJ, Glickson JD. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. NMR Biomed. Apr 3: 2008; in press.
40. Mori S, van Zijl PCM. Diffusion weighting by the trace of the diffusion tensor within a single scan. Magn Reson Med. 1995; 33: 41-52.
41. Yablonskiy DA, Bretthorst GL, Ackerman JJ. Statistical model for diffusion attenuated MR signal. Magnetic Resonance in Medicine. 2003; 50(4): 664-669.
42. Ababneh Z, Beloeil H, Berde CB, Gambarota G, Maier SE, Mulkern RV. Biexponential parameterization of diffusion and T2 relaxation decay curves in a rat muscle edema model: decay curve components and water compartments. Magn Reson Med. 2005; 54(3): 524-531.
43. Rubesova E, Grell A-S, Maertelaer VD, Metens T, Chao S-L, Lemort M. Quantitative diffusion imaging in breast cancer: A clinical prospective study. J. Magn Reson Imaging. 2006; 24: 319-324.
44. Field AS, Alexander AL. Diffusion tensor imaging in cerebral tumor diagnosis and therapy. Topics in Magn Reson Imaging. 2004; 15(5): 315-324.
45. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res. 2007; 13: 443-450.
46. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000; 43: 828-836.
47. Valonen PK, Lehtimäki KK, Väisänen TH, Kettunen MI, Grohn OHJ, Yla-Herttuala S, Kauppinen RA. Water diffusion in a rat glioma during ganciclovir-thymidine kinase gene therapy-induced programmed cell death in vivo: Correlation with cell density. J Magn Reson Imaging. 2004; 19: 389-396.
48. Gauvain KM, Garbow JR, Song S-K, Hirbe AC, Weilbaecher K. MRI detection of early bone metastases in B16 mouse melanoma models. Clin Exp Metastasis. 2005; 22(5): 403-411.
49. McKenna WG, Lenkinski RE, Hendrix RA, Vogele KE, Bloch P. The use of magnetic resonance imaging and spectroscopy in the assessment of patients with head and neck and other superficial human malignancies. Cancer. 1989; 64: 2069-2075.
50. Zhao F, Kuroiwa T, Miyasaka N, Nagaoka T, Nakane M, Tamura A, Mizusawa H. Ultrastructural and MRI study of the substantia nigra evolving exofocal post-ischemic neuronal death in the rat. Neuropathology. 2002; 22(3): 91-105.
51. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer. 2006; 94: 427-435.
52. Charagundla SR, Duvvuri U, Noyszewski EA, Dandora R, Stolpen AH, Leigh JS, Reddy R. 17O-decoupled (1)H spectroscopy and imaging with a surface coil: STEAM decoupling. J. Magn Reson. 2000; 143(1): 39-44.
53. Issels RD, Schlemmer M, Lindner LH. The role of hyperthermia in combined treatment in the management of soft tissue sarcoma. Curr Oncol Rep. 2006; 8(4): 305-309.
54. Fenton BM, Lord EM, Paoni SF. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation. Radiat Res. 2000; 153: 75-83.